Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 09/30/20 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
10 | |
| 09/30/20 | 8-K | Current report filing |
|
25 | |
| 09/25/20 | EFFECT | Notice of Effectiveness |
|
1 | |
| 09/23/20 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 09/23/20 | UPLOAD | SEC-generated letter |
|
1 | |
| 09/15/20 | S-3 | Registration statement for specified transactions by certain issuers |
|
26 | |
| 09/14/20 | 424B7 | Prospectus filed pursuant to Rule 424(b)(7) |
|
2 | |
| 09/01/20 | DEF 14A | Definitive proxy statements |
|
65 | |
| 09/01/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 09/01/20 | 5 | Annual statement of changes in beneficial ownership of securities |
|
2 |
